Ironshore Leadership Team


Stephanie Read

Chief Executive Officer

READ BIO

Stephanie Read

Chief Executive Officer

In addition to serving as the newly appointed CEO of Ironshore, Stephanie will continue to have a seat on the Ironshore Board. Ms. Read also serves as a Non-Executive Director on the Board of ALSP Orchid Acquisition Corporation I (NASDAQ:ALORU). Ms. Read’s 24-year biopharmaceutical career spans Global Research and Development, Medical Affairs, Alliance Management, Commercial and Business Development and Equity Investing. All leadership roles have included driving transformational change within organizations to accelerate top and bottom line growth, and diversification of company portfolios. Ms. Read’s therapy area expertise includes Psychiatry (inventorship of MYDAYIS), Gastroenterology, Oncology & Pain, Infectious Disease, Immunology and Rare Diseases. Ms. Read’s industry appointments include the last 6.5 years with CSL (CSL:ASX) as global VP, Corporate Strategy and Business Development, 7.5 years with AstraZeneca/MedImmune (AZN) in a variety of Medical Affairs, Commercial and Business Development roles, and over 6 years with Shire PLC in R&D and Global Medical Affairs (including inventing, developing and launching new treatments for ADHD).


Stephanie holds a M.Sc. in Biotechnology from The Johns Hopkins University and a B.Sc. in Biology from Virginia Tech.

Bev Incledon, PhD

Chief Scientific Officer

READ BIO

Bev Incledon, PhD

Chief Scientific Officer

Dr. Incledon serves as the Company’s Chief Scientific Officer. Dr. Incledon has over 28 years of pharmaceutical industry experience encompassing large and small molecule drug discovery, pre-clinical, clinical, product and manufacturing process development roles as well as new R&D facility start-up, and research on novel drug delivery technology. Dr. Incledon gained these experiences through roles with increasing responsibility at Syntex Inc., Glaxo Wellcome Inc., Eli Lilly and Company and several start up biotech companies. Over his career he has been a contributor to 21 clinical development stage and 8 marketed products.


Dr. Incledon was a Post-Doctoral Fellow at Cornell University, conducting his research in mathematical modelling of chaperonin assisted oxidative refolding pathways. He obtained his PhD degree in Biophysics studying the kinetics of multi-subunit protein association from the University of Guelph.

Lewis Warrington, MD

Chief Medical Officer

READ BIO

Lewis Warrington, MD

Chief Medical Officer

Dr. Warrington has extensive experience in Psychiatry, having completed a General Adult Psychiatry residency at the University of Virginia and a Child and Adolescent Psychiatry fellowship at the University of Florida. He also completed a Postdoctoral Fellowship in Neuropsychopharmacology at the Mayo Clinic. Over a 20-year career in pharmaceutical medicine in roles of increasing responsibility, Dr. Warrington has worked in multiple disease state areas to include ADHD, Schizophrenia, Bipolar Disorder, Major Depression, and Insomnia with a pedigree spanning Merck, Novartis, Sanofi and Pfizer.

Dr. Warrington earned his medical degree from East Carolina University School of Medicine.

Danny Villeneuve

Chief Commercial Officer

READ BIO

Danny Villeneuve

Chief Commercial Officer

Danny Villeneuve serves as Chief Commercial Officer of Ironshore Pharmaceuticals, responsible for leading the commercial team, including marketing, sales, sales support, sales training and associated capabilities.


Danny has more than 20 years of operational and commercial leadership experience in the biopharmaceutical industry, including 13 years where he was directly involved in the commercialization of multiple ADHD medications both in the US and global market. In addition to ADHD, Danny commercialized products in the CNS, GI, diabetes and obesity markets.


Danny earned his Bachelor of Science in Medical Biology at Université du Québec in Canada.

Nilay Patel

Chief Legal Officer

READ BIO

Nilay Patel

Chief Legal Officer

Nilay Patel is Chief Legal Officer of Ironshore Pharmaceuticals.


Nilay has broad legal experience, from both private practice and as in-house counsel, supporting every stage of pharmaceutical development and commercialization, across several products and disease states.


Nilay holds a JD from Columbia Law School and a BS Biochemistry from NC State University. He is also a registered patent attorney.

Tim Branz

Chief Information Officer

READ BIO

Tim Branz

Chief Information Officer

Tim Branz commenced his career in technology via PWC during the merger of Price Waterhouse / Coopers & Lybrand in 1999. Starting in the Global Technology Solutions division at the National Network Operations Center, he transitioned to Healthcare Revenue Cycle Management where he was able to grow within the business for more than 20 years writing and leading software development efforts of proprietary RCM systems, managing the transition to cloud computing, and spearheading the evolution of security, governance, risk management, and compliance programs, serving in his final position as CIO prior to joining Ironshore’s IT leadership team in 2021. Tim holds a Bachelor’s degree from Stetson University and a Master’s degree in Computer Information Systems from Nova Southeastern University.

Nelson Isabel

Chief Financial Officer

READ BIO

Nelson Isabel

Chief Financial Officer

Nelson F. Isabel serves as the Chief Financial Officer of Ironshore Therapeutics Inc. and has been a pharmaceutical industry executive for 18 years. Prior to joining Ironshore, Mr. Isabel spent seven years at Biovail Corporation (now Bausch Health), Canada’s largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the North American healthcare industry with CIBC World Markets and with Desjardins Securities.​​​​​​​


Mr. Isabel has a B.Sc. in Biology (Experimental Animal Physiology) and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charterholder since 2002.


Micheal Westphall

Chief People Officer

READ BIO

Micheal Westphall

Chief People Officer

Micheal Westphall serves as the Company’s Chief People Officer and has over 20 years of progressive Human Resources experience. Prior to joining Ironshore, Micheal was an HR Consultant, leading client organizations through establishing a strategic HR function. Micheal spent four years as the Global Head of Rewards and HR Operations at AveXis/Novartis Gene Therapies where she built an efficient HR Rewards organization to support the growth of the company from start-up through their first product launch. Micheal has also held various HR leadership roles in private and public organizations including Alight Solutions, Aon, and Abbott Laboratories.

 

Micheal holds an MBA from the University of Wisconsin-Whitewater and Bachelor’s degree from California State University-San Bernardino.

Ironshore BOARD OF DIRECTORS


Scott Myers

Chair of Board

READ BIO

Scott Myers

Chair of Board

Mr. Myers is a proven executive who brings nearly three decades of global pharmaceutical and medical technology most recently as CEO of AMAG, sold to Covis Pharmaceuticals, SA in November of 2020. Mr. Myers is a serial CEO, serving as Chairman and Chief Executive Officer of Rainier Therapeutics, a clinical-stage biotechnology company focused on metastatic bladder cancer that was purchased by Fusion Pharmaceuticals in March of 2020. Prior to joining Rainier, Mr. Myers served as Chief Executive Officer, President and as a director of Cascadian Therapeutics Inc. prior to its acquisition by SeaGen in March of 2018. Mr. Myers also served as Chief Executive Officer of Aerocrine AB, a medical device company from 2011 to 2015 prior to its acquisition by Circassia. Mr. Myers is currently an independent director of Selecta Biosciences where he serves as the Chair of the Compensation and Benefits Committee, as well as a member of the Nominating and Governance Committee. Mr. Myers also serves as the Chairman of the Board and Chairman of the Nomination and Governance committees and is a member of the Audit Committee for Harpoon Therapeutics, a clinical stage oncology. Mr. Myers is also Chairman of the Board for Sensorion, SA, a gene therapy company focused on inner ear diseases. Mr. Myers is also Chairman of the Board of Dynavax Technologies, a Hepatitis B vaccine and COVID Adjuvant commercial stage company.

Stefan Antonsson

Independent Director

READ BIO

Stefan Antonsson

Independent Director

Mr. Antonsson has over 30 years of commercial experience in the pharmaceutical industry, primarily as a senior marketing executive, and he has established a proven track record of contributing to the success of rapidly growing pharmaceutical companies. Stefan was a key member of the Richwood/Shire senior management team and played a leadership role in launching Adderall® and developing Adderall XR, acquiring and launching Carbatrol®, and initiating the development of Intuniv®. Stefan has also held senior marketing positions with Pharmacia and Forest Laboratories and executive positions with Vela Pharmaceuticals and Xanodyne Pharmaceuticals. Stefan has also been involved in several entrepreneurial ventures which successfully developed, licensed, and commercialized CNS products. Stefan also completed a long-term consulting assignment as Senior Vice-President of Marketing for Supernus Pharmaceuticals where he was part of the senior management team that established the commercial function for the company and successfully launched two anti-epilepsy drugs. Stefan earned his BA from Columbia College and MBA from The Stern School of Business, NYU.

Kevin Bain

Independent Director and Chair of Audit Committee

READ BIO

Kevin Bain

Independent Director and Chair of Audit

Committee

Mr. Bain is currently Chief Corporate Development Officer of Cell Research Corporation, a Singapore-based biologics company. This is a clinical-stage company developing a platform of products using stem cells from the umbilical cord lining membrane. From early 2006 through mid-2020, Kevin worked in the generic pharmaceutical and biosimilar business in companies founded and led by Robert Wessman. Kevin joined Alvogen in August 2009 as Chief Financial Officer, with responsibility for all Finance and Information Technology functions for the global Alvogen business. In November 2015, Kevin moved to a sister company named Alvotech as Chief Financial Officer. He has led several financing rounds, raising more than $1.5 billion in total value. Prior to joining Alvogen and Alvotech he spent almost four years with Actavis as Vice President of Finance for the US business of Actavis. From mid-2001 to early 2006, Mr. Bain was VP of Finance with a division of Danaher Corporation. From 1979 to 2001, Mr. Bain held positions of increasing responsibility within the finance organization of the Johnson & Johnson Family of Companies in both Canada and the US, including Vice President of Finance for J&J Medical Products. Mr. Bain graduated from the Accounting program at Fanshawe College in London, Ontario, Canada, and later earned his Certified Management Accountant (CMA) designation. Kevin is currently a Board member and Chair of the Audit Committee of Akorn Pharmaceuticals, a leading US-based specialty pharmaceuticals company.

Ildiko Mehes

Independent Director

READ BIO

Ildiko Mehes

Independent Director

Ms. Mehes is an advisor to investment management firms, consulting firms and pharmaceutical companies about a wide range of risks and opportunities in the pharmaceutical industry. She previously spent 12 years at Teva Pharmaceuticals in a variety of business and legal roles including, most recently, Senior Vice President & General Counsel. Her areas of responsibility in the US and Canada spanned New Product & Portfolio, R&D, Regulatory Affairs, and Legal Affairs. She has extensive expertise in intellectual property, including related to ADHD drugs, and also has significant pharmaceutical M&A experience. Prior to Teva, Ildiko was a pharmaceutical patent and commercial litigator. Ildiko is admitted to the Bars of Massachusetts and Ontario, Canada. She is also the recipient of several awards, including the National Post/ ZSA Canadian General Counsel Award for Litigation Management and the Association of Corporate Counsel’s Global Award for Litigation Management. Ildiko holds a B.A. (Honors) in Economics from Queen’s University, a J.D. from Osgoode Hall Law School, both in Canada, and completed the Advanced Management Program at the Wharton Business School.

Stephanie Read

Chief Executive Officer

READ BIO

Stephanie Read

Chief Executive Office

In addition to serving as the newly appointed CEO of Ironshore, Stephanie will continue to have a seat on the Ironshore Board. Ms. Read also serves as a Non-Executive Director on the Board of ALSP Orchid Acquisition Corporation I (NASDAQ:ALORU). Ms. Read’s 24-year biopharmaceutical career spans Global Research and Development, Medical Affairs, Alliance Management, Commercial and Business Development and Equity Investing. All leadership roles have included driving transformational change within organizations to accelerate top and bottom line growth, and diversification of company portfolios. Ms. Read’s therapy area expertise includes Psychiatry (inventorship of MYDAYIS), Gastroenterology, Oncology & Pain, Infectious Disease, Immunology and Rare Diseases. Ms. Read’s industry appointments include the last 6.5 years with CSL (CSL:ASX) as global VP, Corporate Strategy and Business Development, 7.5 years with AstraZeneca/MedImmune (AZN) in a variety of Medical Affairs, Commercial and Business Development roles, and over 6 years with Shire PLC in R&D and Global Medical Affairs (including inventing, developing and launching new treatments for ADHD).


Stephanie holds a M.Sc. in Biotechnology from The Johns Hopkins University and a B.Sc. in Biology from Virginia Tech.

Sign up for company updates on our products and market news

SUBSCRIBE
Sign-Up

Get the latest company updates on our products and marketing news.

Sign-Up

Get the latest company updates on our products and marketing news.

© 2022 Ironshore | IP001327 09/22 | Site Design: Digital Elevator